Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

Donna M. Graham; Vicky M. Coyle; Richard D. Kennedy; Richard H. Wilson

doi:10.1007/s11888-016-0312-y

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

Donna M. Graham
, Vicky M. Coyle
, Richard D. Kennedy
, Richard H. Wilson^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

45 Citations (Scopus)

628 Downloads (Pure)

Abstract

Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal cancer for molecular stratification and for treatment allocation purposes, including open and planned precision medicine trials. Advances in our understanding, therapeutic strategy and technology will also be outlined.

Original language	English
Pages (from-to)	141-150
Number of pages	10
Journal	Current Colorectal Cancer Reports
Volume	12
Issue number	3
Early online date	18 Apr 2016
DOIs	https://doi.org/10.1007/s11888-016-0312-y
Publication status	Published - Jun 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biomarker stratification
BRAF
c-MET
Colorectal cancer
EGFR
HER2
Microsatellite instability
Molecular subtypes
Pathways
Personalized medicine trials
RAS
Targeted therapy

ASJC Scopus subject areas

Oncology
Gastroenterology
Hepatology

Access to Document

10.1007/s11888-016-0312-yLicence: CC BY

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Final published version, 450 KBLicence: CC BY

Cite this

@article{416cc33e1302474dacb33dff56bf96c9,

title = "Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer",

abstract = "Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal cancer for molecular stratification and for treatment allocation purposes, including open and planned precision medicine trials. Advances in our understanding, therapeutic strategy and technology will also be outlined.",

keywords = "Biomarker stratification, BRAF, c-MET, Colorectal cancer, EGFR, HER2, Microsatellite instability, Molecular subtypes, Pathways, Personalized medicine trials, RAS, Targeted therapy",

author = "Graham, \{Donna M.\} and Coyle, \{Vicky M.\} and Kennedy, \{Richard D.\} and Wilson, \{Richard H.\}",

year = "2016",

month = jun,

doi = "10.1007/s11888-016-0312-y",

language = "English",

volume = "12",

pages = "141--150",

journal = "Current Colorectal Cancer Reports",

issn = "1556-3790",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

AU - Graham, Donna M.

AU - Coyle, Vicky M.

AU - Kennedy, Richard D.

AU - Wilson, Richard H.

PY - 2016/6

Y1 - 2016/6

N2 - Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal cancer for molecular stratification and for treatment allocation purposes, including open and planned precision medicine trials. Advances in our understanding, therapeutic strategy and technology will also be outlined.

AB - Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal cancer for molecular stratification and for treatment allocation purposes, including open and planned precision medicine trials. Advances in our understanding, therapeutic strategy and technology will also be outlined.

KW - Biomarker stratification

KW - BRAF

KW - c-MET

KW - Colorectal cancer

KW - EGFR

KW - HER2

KW - Microsatellite instability

KW - Molecular subtypes

KW - Pathways

KW - Personalized medicine trials

KW - RAS

KW - Targeted therapy

U2 - 10.1007/s11888-016-0312-y

DO - 10.1007/s11888-016-0312-y

M3 - Article

AN - SCOPUS:84964355710

SN - 1556-3790

VL - 12

SP - 141

EP - 150

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

IS - 3

ER -

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this